Bublitz et al., 2023 - Google Patents
The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infectionBublitz et al., 2023
View HTML- Document ID
- 4729216481273017741
- Author
- Bublitz A
- Brauer M
- Wagner S
- Hofer W
- Müsken M
- Deschner F
- Lesker T
- Neumann-Schaal M
- Paul L
- Nübel U
- Bartel J
- Kany A
- Zühlke D
- Bernecker S
- Jansen R
- Sievers S
- Riedel K
- Herrmann J
- Müller R
- Fuchs T
- Strowig T
- Publication year
- Publication venue
- Cell Host & Microbe
External Links
Snippet
Clostridioides difficile infections (CDIs) remain a healthcare problem due to high rates of relapsing/recurrent CDIs (rCDIs). Breakdown of colonization resistance promoted by broad- spectrum antibiotics and the persistence of spores contribute to rCDI. Here, we demonstrate …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6888—Hybridisation probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Piewngam et al. | Pathogen elimination by probiotic Bacillus via signalling interference | |
| Ong et al. | Burkholderia paludis sp. nov., an antibiotic-siderophore producing novel Burkholderia cepacia complex species, isolated from Malaysian tropical peat swamp soil | |
| Sun et al. | Fatty acids regulate stress resistance and virulence factor production for Listeria monocytogenes | |
| Kolling et al. | Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production | |
| Collins et al. | Humanized microbiota mice as a model of recurrent Clostridium difficile disease | |
| Ojha et al. | p-Coumaric acid inhibits the Listeria monocytogenes RecA protein functions and SOS response: An antimicrobial target | |
| Bublitz et al. | The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection | |
| Howerton et al. | Effect of the synthetic bile salt analog CamSA on the hamster model of Clostridium difficile infection | |
| Rajpara et al. | Synergistic effect of various virulence factors leading to high toxicity of environmental V. cholerae non-O1/non-O139 isolates lacking ctx gene: comparative study with clinical strains | |
| Schenck et al. | Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection | |
| Thanissery et al. | A small molecule-screening pipeline to evaluate the therapeutic potential of 2-aminoimidazole molecules against Clostridium difficile | |
| Chellapandi et al. | Clostridium botulinum type A-virulome-gut interactions: a systems biology insight | |
| Liao et al. | Transcriptomic analyses reveal the potential antibacterial mechanism of citral against Staphylococcus aureus | |
| Phan et al. | An aniline-substituted bile salt analog protects both mice and hamsters from multiple Clostridioides difficile strains | |
| Wei et al. | Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics | |
| Wilson et al. | Co-culture with Acinetobacter johnsonii enhances benzalkonium chloride resistance in Salmonella enterica via triggering lipid A modifications | |
| Lu et al. | A potential bio‐control agent from baical skullcap root against listeriosis via the inhibition of sortase A and listeriolysin O | |
| US11666611B2 (en) | Defined therapeutic microbiota and methods of use thereof | |
| Ferreira et al. | Environmentally acquired Bacillus and their role in C. difficile colonization resistance | |
| Trang et al. | Functional properties of maillard reaction products in food: antimicrobial activity of aminoreductone against pathogenic bacteria | |
| Dicks | Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI | |
| Yuille et al. | Optimising gut colonisation resistance against Clostridium difficile infection | |
| Cersosimo et al. | Central in vivo mechanisms by which C. difficile’s proline reductase drives efficient metabolism, growth, and toxin production | |
| Jaramillo et al. | Antibacterials | |
| Yoon et al. | Anti-Tuberculosis Activity of Pediococcus acidilactici Isolated from Young Radish Kimchi against Mycobacterium tuberculosis |